Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...
FierceBiotech12h
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...